Nitric oxide-derived oxidants with a focus on peroxynitrite: Molecular targets, cellular responses and therapeutic implications

Current Pharmaceutical Design

Volumn 17, Issue 35, 2011, Pages 3905-3932

  Calcerrada, P ^a   Peluffo, G ^a   Radi, R ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Antioxidants; Free radicals; Nitration; Nitric oxide; Nitrotyrosine; Oxidation; Oxidative stress; Peroxynitrite

Indexed keywords

3 BENZYL 7 (2 BENZOXAZOLYL)THIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDINE; ACETYLCYSTEINE; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; ANTIOXIDANT; APOCYNIN; ARR 17477; ASCORBIC ACID; BIOPTERIN; BYK 191023; CYSTEINE; EBSELEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; FLAVONOID; LIPID; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITROGEN DIOXIDE; OXIDIZING AGENT; PEROXYNITRITE; PR 39; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; RUBOXISTAURIN; S 17834; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; TEMPOL; THIOCTIC ACID; THIOL DERIVATIVE; TOCOPHEROL; UNCLASSIFIED DRUG; URIC ACID; VAS 2870;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATHEROSCLEROSIS; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CATALYST; CELL DEATH; CYTOTOXICITY; DIABETES MELLITUS; DISEASE MODEL; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNE RESPONSE; IN VIVO STUDY; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MORBIDITY; MORTALITY; MYOCARDITIS; NEOPLASM; NITRATION; NONHUMAN; OXIDATION; PARKINSON DISEASE; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 83455170695     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798357719     Document Type: Review

References (444)

1. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271(5 Pt 1): C1424-C1437.
2. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004 23; 101(12): 4003-4008.
3. Kim K-M, Kim PKM, Kwon Y-G, Bai S-K, Nam W-D, Kim Y-M. Regulation of apoptosis by nitrosative stress. Journal of biochemistry and molecular biology 2002; 35: 127-133.
4. Kroncke KD. Nitrosative stress and transcription. Biol Chem 2003; 384(10-11): 1365-1377.
5. Barthesaghi S, Romero R, Radi R. Nitric Oxide and Derived Oxidants. In: Pantopoulos K, Schipper HM, editors. Principles of Free Radical Biomedicine: Nova Science Publishers, Inc.; 2011.
6. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87(4): 1620-1624.
7. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992 1; 298(2): 446-451.
8. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitriteinduced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288(2): 481-487.
9. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266(7): 4244-4250.
10. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87(1): 315-424.
11. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007; 6(8): 662-680.
12. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357(Pt 3): 593-615.
13. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide; 23(2): 75-93.
14. Carreras MC, Poderoso JJ. Mitochondrial nitric oxide in the signaling of cell integrated responses. Am J Physiol Cell Physiol 2007; 292(5): C1569-C1580.
15. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284(1): R1-R12.
16. Tran QK, Leonard J, Black DJ, Nadeau OW, Boulatnikov IG, Persechini A. Effects of combined phosphorylation at Ser-617 and Ser- 1179 in endothelial nitric-oxide synthase on EC50(Ca2+) values for calmodulin binding and enzyme activation. J Biol Chem 2009; 284(18): 11892-11899.
17. Romero N, Denicola A, Radi R. Red blood cells in the metabolism of nitric oxide-derived peroxynitrite. IUBMB life 2006; 58: 572-580.
18. Hsu JL, Hsieh Y, Tu C, O'Connor D, Nick HS, Silverman DN. Catalytic properties of human manganese superoxide dismutase. J Biol Chem 1996; 271(30): 17687-17691.
19. Goldstein S, Czapski G. The reaction of NO. with O2.- and HO2.: a pulse radiolysis study. Free Radic Biol Med 1995; 19(4): 505-10.
20. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993; 18(4): 195-199.
21. Kissner R, Nauser T, Bugnon P, Lye PG, Koppenol WH. Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol 1997; 10(11): 1285-1292.
22. Radi R, Peluffo G, Alvarez MN, Naviliat M, Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001; 30(5): 463-488.
23. Alvarez MN, Trujillo M, Radi R. Peroxynitrite formation from biochemical and cellular fluxes of nitric oxide and superoxide. Methods Enzymol 2002; 359: 353-366.
24. Radi R, Denicola A, Alvarez B, Ferrer-Sueta G, Rubbo H. The Biological Chemistry of Peroxynitrite. In: Ignarro LJ, editor. Nitric Oxide Biology and Pathobiology. First ed. San Diego: Academic Press; 2000. p. 57-82.
25. Denicola A, Souza JM, Radi R. Diffusion of peroxynitrite across erythrocyte membranes. Proc Natl Acad Sci USA 1998; 95(7): 3566-3571.
26. Bonini MG, Augusto O. Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. J Biol Chem 2001; 276(13): 9749-9754.
27. Quijano C, Alvarez B, Gatti RM, Augusto O, Radi R. Pathways of peroxynitrite oxidation of thiol groups. Biochem J 1997; 322 (Pt 1): 167-173.
28. Shelton MD, Mieyal JJ. Regulation by reversible Sglutathionylation: molecular targets implicated in inflammatory diseases. Mol Cells 2008; 25(3): 332-346.
29. Madej E, Folkes LK, Wardman P, Czapski G, Goldstein S. Thiyl radicals react with nitric oxide to form S-nitrosothiols with rate constants near the diffusion-controlled limit. Free Radic Biol Med 2008; 44(12): 2013-2018.
30. Bonini MG, Radi R, Ferrer-Sueta G, Ferreira AM, Augusto O. Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide. J Biol Chem 1999; 274(16): 10802-10806.
31. Denicola A, Freeman BA, Trujillo M, Radi R. Peroxynitrite reaction with carbon dioxide/bicarbonate: kinetics and influence on peroxynitrite- mediated oxidations. Arch Biochem Biophys 1996; 333(1): 49-58.
32. Merenyi G, Lind J. Free radical formation in the peroxynitrous acid (ONOOH)/peroxynitrite (ONOO-) system. Chem Res Toxicol 1998; 11(4): 243-246.
33. Bartesaghi S, Valez V, Trujillo M, et al. Mechanistic studies of peroxynitrite-mediated tyrosine nitration in membranes using the hydrophobic probe N-t-BOC-L-tyrosine tert-butyl ester. Biochemistry 2006; 45(22): 6813-25.
34. Bartesaghi S, Ferrer-Sueta G, Peluffo G, et al. Protein tyrosine nitration in hydrophilic and hydrophobic environments. Amino Acids 2007; 32(4): 501-515.
35. O'Donnell VB, Eiserich JP, Bloodsworth A, et al. Nitration of unsaturated fatty acids by nitric oxide-derived reactive species. Methods Enzymol 1999; 301: 454-470.
36. Rubbo H, Trostchansky A, O'Donnell VB. Peroxynitrite-mediated lipid oxidation and nitration: mechanisms and consequences. Arch Biochem Biophys 2009; 484(2): 167-172.
37. Augusto O, Bonini MG, Amanso AM, Linares E, Santos CC, De Menezes SL. Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radic Biol Med 2002; 32(9): 841-859.
38. Kirsch M, Lehnig M, Korth HG, Sustmann R, de Groot H. Inhibition of peroxynitrite-induced nitration of tyrosine by glutathione in the presence of carbon dioxide through both radical repair and peroxynitrate formation. Chemistry 2001; 7(15): 3313-3320.
39. Wu W, Chen Y, Hazen SL. Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 1999; 274(36): 25933-25944.
40. Denicola A, Batthyany C, Lissi E, Freeman BA, Rubbo H, Radi R. Diffusion of nitric oxide into low density lipoprotein. J Biol Chem 2002; 277(2): 932-936.
41. Denicola A, Souza JM, Radi R, Lissi E. Nitric oxide diffusion in membranes determined by fluorescence quenching. Arch Biochem Biophys 1996; 328(1): 208-212.
42. Liu X, Miller MJ, Joshi MS, Thomas DD, Lancaster JR, Jr. Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes. Proc Natl Acad Sci USA 1998; 95(5): 2175-2179.
43. Nedospasov A, Rafikov R, Beda N, Nudler E. An autocatalytic mechanism of protein nitrosylation. Proc Natl Acad Sci USA 2000; 97(25): 13543-13548.
44. Gago B, Lundberg JO, Barbosa RM, Laranjinha J. Red winedependent reduction of nitrite to nitric oxide in the stomach. Free Radic Biol Med 2007; 43(9): 1233-1242.
45. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005; 25(5): 915-922.
46. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol 1992; 5(6): 834-842.
47. Peluffo G, Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007; 75(2): 291-302.
48. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003; 25(3-4): 295-311.
49. Okamoto T, Akaike T, Nagano T, et al. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 1997; 342(2): 261-274.
50. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H. Activation of matrix metalloproteinases by peroxynitriteinduced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001; 276(31): 29596-29602.
51. Lalu MM, Wang W, Schulz R. Peroxynitrite in myocardial ischemia- reperfusion injury. Heart Fail Rev 2002; 7(4): 359-369.
52. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002; 53(1): 165-174.
53. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106(12): 1543-1549.
54. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al. Matrix metalloproteinase- 2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003; 57(2): 426-433.
55. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50(4): 329-339.
56. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8(1): 82-89.
57. Ford E, Hughes MN, Wardman P. Kinetics of the reactions of nitrogen dioxide with glutathione, cysteine, and uric acid at physiological pH. Free Radic Biol Med 2002; 32(12): 1314-1323.
58. Arteel GE, Briviba K, Sies H. Protection against peroxynitrite. FEBS Lett 1999; 445(2-3): 226-230.
59. Muyderman H, Nilsson M, Sims NR. Highly selective and prolonged depletion of mitochondrial glutathione in astrocytes markedly increases sensitivity to peroxynitrite. J Neurosci 2004; 24(37): 8019-8028.
60. Marshall KA, Reist M, Jenner P, Halliwell B. The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease. Free Radic Biol Med 1999; 27(5-6): 515-520.
61. Souza JM, Peluffo G, Radi R. Protein tyrosine nitration--functional alteration or just a biomarker? Free Radic Biol Med 2008; 45(4): 357-366.
62. Bartesaghi S, Wenzel J, Trujillo M, et al. Lipid Peroxyl Radicals Mediate Tyrosine Dimerization and Nitration in Membranes. Chem Res Toxicol Feb 19.
63. Brennan ML, Wu W, Fu X, et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 2002; 277(20): 17415-17427.
64. Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxidederived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391(6665): 393-397.
65. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitritemediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 1998; 37(6): 1613-1622.
66. Quijano C, Hernandez-Saavedra D, Castro L, McCord JM, Freeman BA, Radi R. Reaction of peroxynitrite with Mn-superoxide dismutase. Role of the metal center in decomposition kinetics and nitration. J Biol Chem 2001; 276(15): 11631-1168.
67. Gunther MR, Hsi LC, Curtis JF, et al. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation. J Biol Chem 1997; 272(27): 17086-17090
68. Chen YR, Chen CL, Chen W, et al. Formation of protein tyrosine ortho-semiquinone radical and nitrotyrosine from cytochrome cderived tyrosyl radical. J Biol Chem 2004; 279(17): 18054-18062.
69. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem Biophys Res Commun 2003; 305(3): 776-783.
70. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996; 93(21): 11853-11858.
71. MacMillan-Crow LA, Thompson JA. Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch Biochem Biophys 1999; 366(1): 82-8.
72. Nilakantan V, Halligan NL, Nguyen TK, et al. Post-translational modification of manganese superoxide dismutase in acutely rejecting cardiac transplants: role of inducible nitric oxide synthase. J Heart Lung Transplant 2005; 24(10): 1591-1599.
73. Gray KD, MacMillan-Crow LA, Simovic MO, Stain SC, May AK. Pulmonary MnSOD is nitrated following hepatic ischemiareperfusion. Surg Infect (Larchmt) 2004; 5(2): 166-173.
74. Aoyama K, Matsubara K, Fujikawa Y, et al. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol 2000; 47(4): 524-527.
75. Guo W, Adachi T, Matsui R, et al. Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin IIinfused rat kidney. Am J Physiol Heart Circ Physiol 2003; 285(4): H1396-H1403.
76. van der Loo B, Labugger R, Skepper JN, et al. Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med 2000; 192(12): 1731-1744.
77. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Jama 2003; 289(13): 1675-1680.
78. Rouzer CA, Marnett LJ. Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev 2003; 103(6): 2239-2304.
79. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-182.
80. Deeb RS, Hao G, Gross SS, et al. Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite. J Lipid Res 2006; 47(5): 898-911.
81. Goodwin DC, Gunther MR, Hsi LC, et al. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J Biol Chem 1998; 273(15): 8903-8909.
82. Trostchansky A, O'Donnell VB, Goodwin DC, et al. Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: a free radical mechanism of inactivation. Free Radic Biol Med 2007; 42(7): 1029-1038.
83. Deeb RS, Resnick MJ, Mittar D, McCaffrey T, Hajjar DP, Upmacis RK. Tyrosine nitration in prostaglandin H(2) synthase. J Lipid Res 2002; 43(10): 1718-1726.
84. Deeb RS, Shen H, Gamss C, et al. Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol 2006; 168(1): 349-362.
85. Schmidt P, Youhnovski N, Daiber A, et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 2003; 278(15): 12813-12819.
86. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 1997; 378(7): 707-713.
87. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 1996; 382(1-2): 101-104.
88. Davis B, Zou MH. CD40 ligand-dependent tyrosine nitration of prostacyclin synthase in vivo. Circulation 2005; 112(14): 2184-2192.
89. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat 2007; 82(1-4): 119-127.
90. Zou M, Yesilkaya A, Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolate-catalyzed tyrosine nitration. Drug Metab Rev 1999; 31(2): 343-9.
91. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116(4): 1071-1080.
92. He C, Choi HC, Xie Z. Enhanced tyrosine nitration of prostacyclin synthase is associated with increased inflammation in atherosclerotic carotid arteries from type 2 diabetic patients. Am J Pathol; 176(5): 2542-2549.
93. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002; 51(1): 198-203.
94. Gurgul-Convey E, Lenzen S. Protection against cytokine toxicity through endoplasmic reticulum and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells. J Biol Chem; 285(15): 11121-11128.
95. Zou MH, Bachschmid M. Hypoxia-reoxygenation triggers coronary vasospasm in isolated bovine coronary arteries via tyrosine nitration of prostacyclin synthase. J Exp Med 1999; 190(1): 135-139.
96. Vadseth C, Souza JM, Thomson L, et al. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 2004; 279(10): 8820-8826.
97. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol 2001; 33(6): 1053-1063.
98. Viner RI, Ferrington DA, Williams TD, Bigelow DJ, Schoneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-ATPase in skeletal muscle. Biochem J 1999; 340 (Pt 3): 657-669.
99. Adachi T, Matsui R, Xu S, et al. Antioxidant improves smooth muscle sarco/endoplasmic reticulum Ca(2+)-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation. Circ Res 2002; 90(10): 1114-1121.
100. 2+-ATPase in human heart failure. Circulation 2005; 111(8): 988-995.
101. Niles JC, Wishnok JS, Tannenbaum SR. Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: structures and mechanisms of product formation. Nitric Oxide 2006; 14(2): 109-121.
102. Yu H, Venkatarangan L, Wishnok JS, Tannenbaum SR. Quantitation of four guanine oxidation products from reaction of DNA with varying doses of peroxynitrite. Chem Res Toxicol 2005; 18(12): 1849-1857.
103. Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 1999; 424(1-2): 37-49.
104. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res 2001; 88(1): 12-21.
105. Rubbo H, Radi R, Trujillo M, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994; 269(42): 26066-26075.
106. Richter C. Biophysical consequences of lipid peroxidation in membranes. Chem Phys Lipids 1987; 44(2-4): 175-189.
107. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 1993; 330(2): 181-185.
108. Guy RA, Maguire GF, Crandall I, Connelly PW, Kain KC. Characterization of peroxynitrite-oxidized low density lipoprotein binding to human CD36. Atherosclerosis 2001; 155(1): 19-28.
109. Batthyany C, Schopfer FJ, Baker PR, et al. Reversible posttranslational modification of proteins by nitrated fatty acids in vivo. J Biol Chem 2006; 281(29): 20450-20463.
110. Baker PR, Schopfer FJ, O'Donnell VB, Freeman BA. Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic Biol Med 2009; 46(8): 989-1003.
111. Freeman BA, Baker PR, Schopfer FJ, Woodcock SR, Napolitano A, d'Ischia M. Nitro-fatty acid formation and signaling. J Biol Chem 2008; 283(23): 15515-15519.
112. Trostchansky A, Rubbo H. Nitrated fatty acids: mechanisms of formation, chemical characterization, and biological properties. Free Radic Biol Med 2008; 44(11): 1887-1896.
113. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 2003; 37(2): 121-127.
114. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95(16): 9220-9225.
115. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113(13): 1708-1714.
116. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003; 278(25): 22546-22554.
117. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999; 263(3): 681-684.
118. Pryor WA. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic Biol Med 2000; 28(1): 141-164.
119. Ferrer-Sueta G, Radi R. Chemical biology of peroxynitrite: kinetics, diffusion, and radicals. ACS Chem Biol 2009; 4(3): 161-177.
120. Klotz LO, Sies H. Defenses against peroxynitrite: selenocompounds and flavonoids. Toxicol Lett 2003; 140-41: 125-132.
121. Radi R, Cassina A, Hodara R, Quijano C, Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002; 33(11): 1451-64.
122. Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1999; 1411(2-3): 351-369.
123. Brown GC, Borutaite V. Nitric oxide, cytochrome c and mitochondria. Biochem Soc Symp 1999; 66: 17-25.
124. Pearce LL, Kanai AJ, Epperly MW, Peterson J. Nitrosative stress results in irreversible inhibition of purified mitochondrial complexes I and III without modification of cofactors. Nitric Oxide 2005; 13(4): 254-263.
125. Radi R, Cassina A, Hodara R. Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem 2002; 383(3-4): 401-409.
126. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994; 308(1): 89-95.
127. Batthyany C, Souza JM, Duran R, Cassina A, Cervenansky C, Radi R. Time course and site(s) of cytochrome c tyrosine nitration by peroxynitrite. Biochemistry 2005; 44(22): 8038-8046.
128. Cassina AM, Hodara R, Souza JM, et al. Cytochrome c nitration by peroxynitrite. J Biol Chem 2000; 275(28): 21409-21415.
129. Jang B, Han S. Biochemical properties of cytochrome c nitrated by peroxynitrite. Biochimie 2006; 88(1): 53-58.
130. Castro L, Rodriguez M, Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J Biol Chem 1994; 269(47): 29409-29415.
131. Han D, Canali R, Garcia J, Aguilera R, Gallaher TK, Cadenas E. Sites and mechanisms of aconitase inactivation by peroxynitrite: modulation by citrate and glutathione. Biochemistry 2005; 44(36): 1986-1996.
132. Tortora V, Quijano C, Freeman B, Radi R, Castro L. Mitochondrial aconitase reaction with nitric oxide, S-nitrosoglutathione, and peroxynitrite: mechanisms and relative contributions to aconitase inactivation. Free Radic Biol Med 2007; 42(7): 1075-1088.
133. Stachowiak O, Dolder M, Wallimann T, Richter C. Mitochondrial creatine kinase is a prime target of peroxynitrite-induced modification and inactivation. J Biol Chem 1998; 273(27): 16694-16699.
134. Forsmark-Andree P, Persson B, Radi R, Dallner G, Ernster L. Oxidative modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles: effect of endogenous ubiquinol. Arch Biochem Biophys 1996; 336(1): 113-120.
135. Quijano C, Cassina A, Castro L, Rodriguez M, Radi R. Nitric oxide, cell signaling and gene expression. In: Lamas S, Cadenas E, editors. Oxidative stress and disease. Boca Ratón FL: CRC Press; 2005.
136. Shacka JJ, Sahawneh MA, Gonzalez JD, Ye YZ, D'Alessandro TL, Estevez AG. Two distinct signaling pathways regulate peroxynitrite- induced apoptosis in PC12 cells. Cell Death Differ 2006; 13(9): 1506-1514.
137. Vicente S, Perez-Rodriguez R, Olivan AM, Martinez Palacian A, Gonzalez MP, Oset-Gasque MJ. Nitric oxide and peroxynitrite induce cellular death in bovine chromaffin cells: evidence for a mixed necrotic and apoptotic mechanism with caspases activation. J Neurosci Res 2006; 84(1): 78-96.
138. Virag L, Marmer DJ, Szabo C. Crucial role of apopain in the peroxynitrite- induced apoptotic DNA fragmentation. Free Radic Biol Med 1998; 25(9): 1075-1082.
139. Vieira HL, Belzacq AS, Haouzi D, et al. The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4- hydroxynonenal. Oncogene 2001; 20(32): 4305-4316.
140. Brookes PS, Darley-Usmar VM. Role of calcium and superoxide dismutase in sensitizing mitochondria to peroxynitrite-induced permeability transition. Am J Physiol Heart Circ Physiol 2004; 286(1): H39-H46.
141. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett 2000; 466(1): 6-10.
142. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 2003; 140-141: 113-124.
143. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996; 93(5): 1753-1758.
144. Koh DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 2005; 52(1): 5-14.
145. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 1999; 96(24): 13978-13982.
146. Liaudet L, Oddo M. Role of poly(adenosine diphosphate-ribose) polymerase 1 in septic peritonitis. Curr Opin Crit Care 2003; 9(2): 152-158.
147. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 2008; 173(1): 2-13.
148. Huang D, Yang CZ, Yao L, Wang Y, Liao YH, Huang K. Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina. Arch Med Res 2008; 39(8): 775-784.
149. Toth-Zsamboki E, Horvath E, Vargova K, et al. Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med 2006; 12(9-10): 221-228.
150. Yao L, Huang K, Huang D, Wang J, Guo H, Liao Y. Acute myocardial infarction induced increases in plasma tumor necrosis factor- alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell. Int J Cardiol 2008; 123(3): 366-368.
151. Love S, Barber R, Wilcock GK. Neuronal accumulation of poly(ADP-ribose) after brain ischaemia. Neuropathol Appl Neurobiol 1999; 25(2): 98-103.
152. Kim SH, Engelhardt JI, Henkel JS, et al. Widespread increased expression of the DNA repair enzyme PARP in brain in ALS. Neurology 2004; 62(2): 319-322.
153. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 1999; 122 (Pt 2): 247-253.
154. Soos J, Engelhardt JI, Siklos L, Havas L, Majtenyi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport 2004; 15(11): 1715-1718.
155. Shibuya A, Wada K, Nakajima A, et al. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage- like cell line, RAW 264. FEBS Lett 2002; 525(1-3): 43-47.
156. Freels JL, Nelson DK, Hoyt JC, et al. Enhanced activity of human IL-10 after nitration in reducing human IL-1 production by stimulated peripheral blood mononuclear cells. J Immunol 2002; 169(8): 4568-4571.
157. Matata BM, Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem 2002; 277(3): 2330-2305.
158. Alvarez MN, Peluffo G, Piacenza L, Radi R. Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity. J Biol Chem; 286(8): 6627-6640.
159. Ye YZ, Strong M, Huang ZQ, Beckman JS. Antibodies that recognize nitrotyrosine. Methods Enzymol 1996; 269: 201-209.
160. Thomson L, Christie J, Vadseth C, et al. Identification of immunoglobulins that recognize 3-nitrotyrosine in patients with acute lung injury after major trauma. Am J Respir Cell Mol Biol 2007; 36(2): 152-157.
161. Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR. Cutting edge: MHC class II-restricted peptides containing the inflammation- associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J Immunol 2003; 171(2): 528-532.
162. Herzog J, Maekawa Y, Cirrito TP, Illian BS, Unanue ER. Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells. Proc Natl Acad Sci USA 2005; 102(22): 7928-7933.
163. Hsu HC, Zhou T, Kim H, et al. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis Rheum 2006; 54(1): 343-355.
164. Khan F, Ali R. Antibodies against nitric oxide damaged poly Ltyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J Biochem Mol Biol 2006; 39(2): 189-196.
165. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91(3C): 31S-38S.
166. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291(3): H985-H1002.
167. Mihm MJ, Jing L, Bauer JA. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 2000; 36(2): 182-7.
168. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000 10; 87(10): 840-844.
169. Smythe CD, Skinner VO, Bruckdorfer KR, Haskard DO, Landis RC. The state of macrophage differentiation determines the TNF alpha response to nitrated lipoprotein uptake. Atherosclerosis 2003; 170(2): 213-221.
170. Leeuwenburgh C, Hardy MM, Hazen SL, et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997 17; 272(3): 1433-1436.
171. Beckmann JS, Ye YZ, Anderson PG, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 1994; 375(2): 81-88.
172. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75(1): 77-85.
173. Depre C, Havaux X, Renkin J, Vanoverschelde JL, Wijns W. Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque. Cardiovasc Res 1999; 41(2): 465-472.
174. Hunter GC, Henderson AM, Westerband A, et al. The contribution of inducible nitric oxide and cytomegalovirus to the stability of complex carotid plaque. J Vasc Surg 1999; 30(1): 36-49; discussion 50.
175. Sucu N, Unlu A, Tamer L, et al. 3-Nitrotyrosine in atherosclerotic blood vessels. Clin Chem Lab Med 2003; 41(1): 23-25.
176. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J
177. Bianchi C, Wakiyama H, Faro R, et al. A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg 2002; 74(4): 201-207.
178. Levrand S, Vannay-Bouchiche C, Pesse B, et al. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 2006; 41(6): 886-895.
179. Hayashi Y, Sawa Y, Ohtake S, Fukuyama N, Nakazawa H, Matsuda H. Peroxynitrite formation from human myocardium after ischemia-reperfusion during open heart operation. Ann Thorac Surg 2001; 72(2): 571-576.
180. Pacher P, Szabo C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 2006; 6(2): 136-141.
181. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 2009; 156(5): 713-727.
182. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6): 1615-1625.
183. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96(1): 25-28.
184. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005; 7(11-12): 1568-1580.
185. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34(12): 1563-1574.
186. Seghrouchni I, Drai J, Bannier E, et al. Oxidative stress parameters in type I, type II and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency. Clin Chim Acta 2002; 321(1-2): 89-96.
187. VanderJagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL. Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 2001; 34(4): 265-270.
188. Varvarovska J, Racek J, Stozicky F, Soucek J, Trefil L, Pomahacova R. Parameters of oxidative stress in children with Type 1 diabetes mellitus and their relatives. J Diabetes Complications 2003; 17(1): 7-10.
189. Brahn E, Banquerigo ML, Firestein GS, Boyle DL, Salzman AL, Szabo C. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. J Rheumatol 1998; 25(9): 1785-1793.
190. Mabley JG, Liaudet L, Pacher P, et al. Part II: beneficial effects of the peroxynitrite decomposition catalyst FP15 in murine models of arthritis and colitis. Mol Med 2002; 8(10): 581-590.
191. Mapp PI, Klocke R, Walsh DA, et al. Localization of 3- nitrotyrosine to rheumatoid and normal synovium. Arthritis Rheum 2001; 44(7): 1534-1539.
192. Sandhu JK, Robertson S, Birnboim HC, Goldstein R. Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2003; 30(6): 1173-1181.
193. Dijkstra G, Moshage H, van Dullemen HM, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998; 186(4): 416-421.
194. Kimura H, Hokari R, Miura S, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998; 42(2): 180-187.
195. Singer, II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111(4): 871-885.
196. Zingarelli B, Cuzzocrea S, Szabo C, Salzman AL. Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther 1998; 287(3): 1048-1055.
197. Victor VM, Rocha M, Esplugues JV, De la Fuente M. Role of free radicals in sepsis: antioxidant therapy. Curr Pharm Des 2005; 11(24): 3141-3158.
198. Kozlov AV, Szalay L, Umar F, et al. Epr analysis reveals three tissues responding to endotoxin by increased formation of reactive oxygen and nitrogen species. Free Radic Biol Med 2003; 34(12): 1555-1562.
199. el-Dwairi Q, Comtois A, Guo Y, Hussain SN. Endotoxin-induced skeletal muscle contractile dysfunction: contribution of nitric oxide synthases. Am J Physiol 1998; 274(3 Pt 1): C770-C779.
200. Lancel S, Tissier S, Mordon S, et al. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol 2004; 43(12): 2348-2358.
201. Ozdulger A, Cinel I, Unlu A, et al. Poly(Adp-ribose) synthetase inhibition prevents lipopolysaccharide-induced peroxynitrite mediated damage in diaphragm. Pharmacol Res 2002; 46(1): 67-73.
202. Szabo C, Salzman AL, Ischiropoulos H. Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 1995; 363(3): 235-238.
203. Fukuyama N, Takebayashi Y, Hida M, Ishida H, Ichimori K, Nakazawa H. Clinical evidence of peroxynitrite formation in chronicrenal failure patients with septic shock. Free Radic Biol Med 1997; 22(5): 771-774.
204. Kooy NW, Lewis SJ, Royall JA, Ye YZ, Kelly DR, Beckman JS. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit Care Med 1997; 25(5): 812-819.
205. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004; 10 Suppl: S18-S25.
206. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med; 48(5): 629-641.
207. Estevez AG, Spear N, Manuel SM, Barbeito L, Radi R, Beckman JS. Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture. Prog Brain Res 1998; 118: 269-280.
208. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 1999; 30(2): 153-163.
209. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993; 364(6438): 584.
210. Ye Y, Quijano C, Robinson KM, et al. Prevention of peroxynitriteinduced apoptosis of motor neurons and PC12 cells by tyrosinecontaining peptides. J Biol Chem 2007; 282(9): 6324-6337.
211. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290(5493): 985-989.
212. Hodara R, Norris EH, Giasson BI, et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004; 279(46): 47746-47753.
213. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003; 278(29): 27230-27240.
214. Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem 2004; 279(11): 10128-10135.
215. Reynolds MR, Berry RW, Binder LI. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry 2005; 44(5): 1690-1700.
216. Reynolds MR, Lukas TJ, Berry RW, Binder LI. Peroxynitritemediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. Biochemistry 2006; 45(13): 4314-4326.
217. Casoni F, Basso M, Massignan T, et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem 2005; 280(16): 16295- 304.
218. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002; 23(5): 655-664.
219. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52(2): 381-389.
220. Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998; 44(5): 819-824.
221. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6(7): 521-534.
222. Suzuki N, Yasui M, Geacintov NE, Shafirovich V, Shibutani S. Miscoding events during DNA synthesis past the nitration-damaged base 8-nitroguanine. Biochemistry 2005; 44(25): 9238-9245.
223. Mabley JG, Pacher P, Bai P, et al. Suppression of intestinal polyposis in Apcmin/+ mice by targeting the nitric oxide or poly(ADPribose) pathways. Mutat Res 2004; 548(1-2): 107-116.
224. Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376(2): 333-337.
225. Amaro S, Canovas D, Castellanos M, et al. The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke; 5(4): 325-328.
226. Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R. Mercaptoethylguanidine and guanidine inhibitors of nitricoxide synthase react with peroxynitrite and protect against peroxynitrite- induced oxidative damage. J Biol Chem 1997; 272(14): 9030-9036.
227. Trujillo M, Radi R. Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols. Arch Biochem Biophys 2002; 397(1): 91-98.
228. Moldeus P, Cotgreave IA. N-acetylcysteine. Methods Enzymol 1994; 234: 482-492.
229. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alphalipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009; 1790(10): 1149-1160.
230. Rubbo H, Radi R, Anselmi D, et al. Nitric oxide reaction with lipid peroxyl radicals spares alpha-tocopherol during lipid peroxidation. Greater oxidant protection from the pair nitric oxide/alphatocopherol than alpha-tocopherol/ascorbate. J Biol Chem 2000; 275(15): 10812-10818.
231. Peluffo G, Calcerrada P, Piacenza L, Pizzano N, Radi R. Superoxide- mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol 2009; 296(6): H1781-H192.
232. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008(2): CD007176.
233. Hertog MG, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 1995; 155(4): 381-386.
234. Schewe T, Steffen Y, Sies H. How do dietary flavanols improve vascular function? A position paper. Arch Biochem Biophys 2008; 476(2): 102-106.
235. Schewe T, Sies H. Myeloperoxidase-induced lipid peroxidation of LDL in the presence of nitrite. Protection by cocoa flavanols. Biofactors 2005; 24(1-4): 49-58.
236. Sies H, Schewe T, Heiss C, Kelm M. Cocoa polyphenols and inflammatory mediators. Am J Clin Nutr 2005; 81(1 Suppl): 304S-312S.
237. Steffen Y, Schewe T, Sies H. (-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase. Biochem Biophys Res Commun 2007; 359(3): 828-833.
238. Gonzalez-Gallego J, Sanchez-Campos S, Tunon MJ. Antiinflammatory properties of dietary flavonoids. Nutr Hosp 2007; 22(3): 287-293.
239. Fernandes DC, Medinas DB, Alves MJ, Augusto O. Tempol diverts peroxynitrite/carbon dioxide reactivity toward albumin and cells from protein-tyrosine nitration to protein-cysteine nitrosation. Free Radic Biol Med 2005; 38(2): 189-200.
240. Soule BP, Hyodo F, Matsumoto K, et al. The chemistry and biology of nitroxide compounds. Free Radic Biol Med 2007; 42(11): 1632-1650.
241. Ye Y, Quijano C, Robinson KM, et al. Prevention of peroxynitriteinduced apoptosis of motor neurons and PC12 cells by tyrosinecontaining peptides. J Biol Chem 2007; 282: 6324-37.
242. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87(1): 245-313.
243. Aldieri E, Riganti C, Polimeni M, et al. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 2008; 9(8): 686-696.
244. Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 2007; 50(1): 9-16.
245. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endotheliumdependent vasodilation caused by hyperglycemia in humans. Circ Res 2002; 90(1): 107-111.
246. Yamamoto S, Golanov EV, Berger SB, Reis DJ. Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat. J Cereb Blood Flow Metab 1992; 12(5): 717-726.
247. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32(1): 21-30.
248. Bakker J, Grover R, McLuckie A, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32(1): 1-12.
249. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14(5): 753-759.
250. Paige JS, Jaffrey SR. Pharmacologic manipulation of nitric oxide signaling: targeting NOS dimerization and protein-protein interactions. Current topics in medicinal chemistry 2007; 7: 97-114.
251. Ferrer-Sueta G, Radi R. Chemical biology of peroxynitrite: kinetics, diffusion, and radicals. ACS chemical biology 2009; 4: 161-177.
252. Trujillo M, Ferrer-Sueta G, Radi R. Peroxynitrite detoxification and its biologic implications. Antioxidants & redox signaling 2008; 10: 1607-1620.
253. Jensen MP, Riley DP. Peroxynitrite decomposition activity of iron porphyrin complexes. Inorg Chem 2002; 41(18): 4788-4797.
254. Ferrer-Sueta G, Hannibal L, Batinic-Haberle I, Radi R. Reduction of manganese porphyrins by flavoenzymes and submitochondrial particles: a catalytic cycle for the reduction of peroxynitrite. Free Radic Biol Med 2006; 41(3): 503-512.
255. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, et al. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 2003; 278(30): 27432-27438.
256. Spasojevic I, Chen Y, Noel TJ, et al. Mn porphyrin-based superoxide dismutase (SOD) mimic, MnIIITE-2-PyP5+, targets mouse heart mitochondria. Free Radic Biol Med 2007; 42(8): 1193-1200.
257. Haruyama T, Asayama S, Kawakami H. Highly amphiphilic manganese porphyrin for the mitochondrial targeting antioxidant. J Biochem; 147(2): 153-156.
258. Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 2006; 7(1): 70-80.
259. Giles GI, Fry FH, Tasker KM, et al. Evaluation of sulfur, selenium and tellurium catalysts with antioxidant potential. Org Biomol Chem 2003; 1(23): 4317-4322.
260. Masumoto H, Sies H. The reaction of ebselen with peroxynitrite. Chem Res Toxicol 1996; 9(1): 262-267.
261. Briviba K, Roussyn I, Sharov VS, Sies H. Attenuation of oxidation and nitration reactions of peroxynitrite by selenomethionine, selenocystine and ebselen. Biochem J 1996; 3 19 (Pt 1): 13-15.
262. Parnham M, Sies H. Ebselen: prospective therapy for cerebral ischaemia. Expert Opin Investig Drugs 2000; 9(3): 607-619.
263. Manzanares W, Biestro A, Torre MH, Galusso F, Facchin G, Hardy G. High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation. Intensive Care Med 2011; 37(7): 1120-1127.
264. Jacob C, Arteel GE, Kanda T, Engman L, Sies H. Water-soluble organotellurium compounds: catalytic protection against peroxynitrite and release of zinc from metallothionein. Chem Res Toxicol 2000; 13(1): 3-9.
265. Briviba K, Tamler R, Klotz LO, Engman L, Cotgreave IA, Sies H. Protection by organotellurium compounds against peroxynitritemediated oxidation and nitration reactions. Biochem Pharmacol 1998; 55(6): 817-823.
266. Mugesh G, du Mont WW, Sies H. Chemistry of biologically important synthetic organoselenium compounds. Chemical reviews 2001; 101: 2125-2179.
267. Nogueira CW, Zeni G, Rocha JBT. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chemical reviews 2004; 104: 6255-6285.
268. Smith RA, Hartley RC, Murphy MP. Mitochondria-Targeted Small Molecule Therapeutics and Probes. Antioxid Redox Signal 6.
269. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-656.
270. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005; 280(22): 21295-21312.
271. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279(33): 34682-34690.
272. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110(3): 285-288.
273. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129-1135.
274. Shishehbor MH, Aviles RJ, Brennan ML, Fet al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA: the journal of the American Medical Association 2003; 289: 1675-1680.
275. Adachi T. Modulation of vascular sarco/endoplasmic reticulum calcium ATPase in cardiovascular pathophysiology. Adv Pharmacol; 59: 165-195.
276. Knyushko TV, Sharov VS, Williams TD, Schoneich C, Bigelow DJ. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry 2005; 44(39): 13071-1381.
277. Lancel S, Qin F, Lennon SL, et al. Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in Galphaq-overexpressing mice. Circ Res; 107(2): 228-232.
278. Tang WH, Kravtsov GM, Sauert M, et al. Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. J Mol Cell Cardiol; 49(1): 58-69.
279. Hodnett BL, Dearman JA, Carter CB, Hester RL. Attenuated PGI2 synthesis in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2009; 296(3): R715-R721.
280. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114(6): 784-794.
281. Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 2009; 122(2): 140-149.
282. Zou M, Jendral M, Ullrich V. Prostaglandin endoperoxidedependent vasospasm in bovine coronary arteries after nitration of prostacyclin synthase. Br J Pharmacol 1999; 126(6): 1283-1292.
283. Marcondes S, Turko IV, Murad F. Nitration of succinyl-CoA: 3- oxoacid CoA-transferase in rats after endotoxin administration. Proc Natl Acad Sci USA 2001; 98(13): 7146-7151.
284. Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA: 3-oxoacid CoAtransferase. Am J Physiol Heart Circ Physiol 2001; 281(6): H2289-H2294.
285. Wang Y, Peng F, Tong W, Sun H, Xu N, Liu S. The nitrated proteome in heart mitochondria of the db/db mouse model: characterization of nitrated tyrosine residues in SCOT. J Proteome Res 6; 9(8): 4254-4263.
286. Parastatidis I, Thomson L, Fries DM, et al. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice. Circ Res 2007; 101(4): 368-76.
287. Heffron SP, Parastatidis I, Cuchel M, et al. Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radic Biol Med 2009; 47(8): 1140-1146.
288. Parastatidis I, Thomson L, Burke A, et al. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 2008; 283(49): 33846-33853.
289. Yu Z, Xu X, Xiang Z, Zhou J, Zhang Z, Hu C, et al. Nitrated alphasynuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS One; 5(4): e9956.
290. Crow JP, Ye YZ, Strong M, Kirk M, Barnes S, Beckman JS. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J Neurochem 1997; 69(5): 1945-1953.
291. Hamilton RT, Asatryan L, Nilsen JT, et al. LDL protein nitration: implication for LDL protein unfolding. Arch Biochem Biophys 2008; 479(1): 1-14.
292. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes; 59(4): 1038-1045.
293. Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res; 51(7): 1849-1858.
294. Zheng L, Settle M, Brubaker G, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005; 280(1): 38-47.
295. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000; 275(24): 18344-18349.
296. Reynolds MR, Berry RW, Binder LI. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry 2005; 44(42): 13997-14009.
297. Cumming RC, Schubert D. Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. Faseb J 2005; 19(14): 2060-2062.
298. Nakajima H, Amano W, Fujita A, et al. The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress-induced aggregation and cell death. J Biol Chem 2007; 282(36): 26562-26574.
299. Anraku M, Takeuchi K, Watanabe H, et al. Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. J Pharm Sci 7.
300. Terawaki H, Takada Y, Era S, et al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial; 14(5): 465-471.
301. Turell L, Botti H, Carballal S, Radi R, Alvarez B. Sulfenic acid--a key intermediate in albumin thiol oxidation. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877(28): 3384-3392.
302. Wendt S, Schlattner U, Wallimann T. Differential effects of peroxynitrite on human mitochondrial creatine kinase isoenzymes. Inactivation, octamer destabilization, and identification of involved residues. J Biol Chem 2003; 278(2): 1125-1130.
303. Suofu Y, Clark J, Broderick J, et al. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats. J Neurochem; 115(5): 1266-1276.
304. Botti H, Trostchansky A, Batthyany C, Rubbo H. Reactivity of peroxynitrite and nitric oxide with LDL. IUBMB Life 2005; 57(6): 407-412.
305. Fujii S, Sawa T, Ihara H, et al. The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response. J Biol Chem; 285(31): 23970-23984.
306. Kirsch M, de Groot H. Reaction of peroxynitrite with reduced nicotinamide nucleotides, the formation of hydrogen peroxide. J Biol Chem 1999; 274(35): 24664-24670.
307. Cromheeke KM, Kockx MM, De Meyer GR, et al. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/ peroxidation in human atherosclerotic plaques. Cardiovasc Res 1999; 43(3): 744-754.
308. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitritemediated reperfusion injury. J Biol Chem 1996; 271(46): 29223-29230.
309. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 1997; 33(2): 422-432.
310. Zweier JL, Fertmann J, Wei G. Nitric oxide and peroxynitrite in postischemic myocardium. Antioxid Redox Signal 2001; 3(1): 11-22.
311. Ma XL, Lopez BL, Liu GL, Christopher TA, Ischiropoulos H. Peroxynitrite aggravates myocardial reperfusion injury in the isolated perfused rat heart. Cardiovasc Res 1997; 36(2): 195-204.
312. Tecder-Unal M, Kanzyk Y. Peroxynitrite in reperfusion arrhythmias and its whole blood chemiluminescence results. Pharmacol Res 2004; 49(1): 7-16.
313. Liu P, Hock CE, Nagele R, Wong PY. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol 1997; 272(5 Pt 2): H2327-H2336.
314. Lee WH, Gounarides JS, Roos ES, Wolin MS. Influence of peroxynitrite on energy metabolism and cardiac function in a rat ischemia-reperfusion model. Am J Physiol Heart Circ Physiol 2003; 285(4): H1385-H1395.
315. Xie YW, Kaminski PM, Wolin MS. Inhibition of rat cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation. Circ Res 1998; 82(8): 891-897.
316. Chaves AA, Mihm MJ, Schanbacher BL, et al. Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues. Cardiovasc Res 2003; 60(1): 108-118.
317. Sakurai M, Fukuyama N, Iguchi A, et al. Quantitative analysis of cardiac 3-L-nitrotyrosine during acute allograft rejection in an experimental heart transplantation. Transplantation 1999; 68(11): 1818-1822.
318. Szabolcs M, Michler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to induction of nitric oxide synthase. Circulation 1996; 94(7): 1665-1673.
319. Szabolcs MJ, Ravalli S, Minanov O, Sciacca RR, Michler RE, Cannon PJ. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 1998; 65(6): 804-812.
320. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104(2): 174-80.
321. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol; 8(9).
322. Eliasson MJ, Huang Z, Ferrante RJ, et al. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J Neurosci 1999; 19(14): 5910-5918.
323. Hirabayashi H, Takizawa S, Fukuyama N, Nakazawa H, Shinohara Y. 7-Nitroindazole attenuates nitrotyrosine formation in the early phase of cerebral ischemia-reperfusion in mice. Neurosci Lett 1999; 268(2): 111-113.
324. Ohtaki H, Funahashi H, Dohi K, et al. Suppression of oxidative neuronal damage after transient middle cerebral artery occlusion in mice lacking interleukin-1. Neurosci Res 2003; 45(3): 313-324.
325. Yu ZF, Bruce-Keller AJ, Goodman Y, Mattson MP. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998; 53(5): 613-625.
326. Imai H, Graham DI, Masayasu H, Macrae IM. Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic Biol Med 2003; 34(1): 56-63.
327. Bouloumie A, Bauersachs J, Linz W, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 1997; 30(4): 934-941.
328. Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. Faseb J 2004; 18(1): 94-101.
329. Hong HJ, Hsiao G, Cheng TH, Yen MH. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001; 38(5): 1044-1048.
330. Suzuki A, Yamamoto N, Jokura H, et al. Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens 2006; 24(6): 1065-1073.
331. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA. Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem Pharmacol 2003; 65(7): 1189-1197.
332. Szabo C, Pacher P, Zsengeller Z, et al. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004; 10(1-6): 28-35.
333. Szilvassy Z, Csont T, Pali T, Droy-Lefaix MT, Ferdinandy P. Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine. J Vasc Res 2001; 38(1): 39-46.
334. Li R, Wang WQ, Zhang H, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 2007; 293(6): E1703-E1708.
335. Eid HM, Lyberg T, Larsen J, Arnesen H, Seljeflot I. Reactive oxygen species generation by leukocytes in populations at risk for atherosclerotic disease. Scand J Clin Lab Invest 2002; 62(6): 431-439.
336. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44(7): 834-838.
337. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87(12): 1123-1132.
338. Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G. Oxidative stress and insulin requirements in patientswith recent-onset type 1 diabetes. J Clin Endocrinol Metab 2003; 88(4): 1624-1628.
339. Tannous M, Rabini RA, Vignini A, et al. Evidence for iNOSdependent peroxynitrite production in diabetic platelets. Diabetologia 1999; 42(5): 539-544.
340. Esberg LB, Ren J. Role of nitric oxide, tetrahydrobiopterin and peroxynitrite in glucose toxicity-associated contractile dysfunction in ventricular myocytes. Diabetologia 2003; 46(10): 1419-1427.
341. Szabo C, Zanchi A, Komjati K, et al. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 2002; 106(21): 2680-2686.
342. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 2000; 57(5): 1968-1972.
343. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003; 44(7): 3135-3143.
344. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162(6): 1995-2004.
345. Connor JR, Manning PT, Settle SL, et al. Suppression of adjuvantinduced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995; 273(1-2): 15-24.
346. Cuzzocrea S, Chatterjee PK, Mazzon E, et al. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 2002; 453(1): 119-129.
347. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians 1999; 111(6): 611-621.
348. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum; 62(7): 2064-2072.
349. Frostegard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52(1): 192-200.
350. Lundberg JO, Hellstrom PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994; 344(8938): 1673-1674.
351. Crouser ED, Julian MW, Weinstein DM, Fahy RJ, Bauer JA. Endotoxin- induced ileal mucosal injury and nitric oxide dysregulation are temporally dissociated. Am J Respir Crit Care Med 2000; 161(5): 1705-1712.
352. Lu Y, Wang X, Cederbaum AI. Lipopolysaccharide-induced liver injury in rats treated with the CYP2E1 inducer pyrazole. Am J Physiol Gastrointest Liver Physiol 2005; 289(2): G308-G319.
353. Zhang C, Walker LM, Mayeux PR. Role of nitric oxide in lipopolysaccharide- induced oxidant stress in the rat kidney. Biochem Pharmacol 2000; 59(2): 203-209.
354. Alvarez S, Boveris A. Mitochondrial nitric oxide metabolism in rat muscle during endotoxemia. Free Radic Biol Med 2004; 37(9): 1472-1478.
355. Goode HF, Cowley HC, Walker BE, Howdle PD, Webster NR. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit Care Med 1995; 23(4): 646-651.
356. Takeda K, Shimada Y, Amano M, Sakai T, Okada T, Yoshiya I. Plasma lipid peroxides and alpha-tocopherol in critically ill patients. Crit Care Med 1984; 12(11): 957-959.
357. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360(9328): 219-223.
358. Boulos M, Astiz ME, Barua RS, Osman M. Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit Care Med 2003; 31(2): 353-358.
359. Gatto EM, Riobo NA, Carreras MC, et al. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 2000; 4(5): 534-539.
360. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998; 57(4): 338-342.
361. Oh-hashi K, Maruyama W, Yi H, Takahashi T, Naoi M, Isobe K. Mitogen-activated protein kinase pathway mediates peroxynitriteinduced apoptosis in human dopaminergic neuroblastoma SHSY5Y cells. Biochem Biophys Res Commun 1999; 263(2): 504-509.
362. Ara J, Przedborski S, Naini AB, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA 1998 23; 95(13): 7659-7663.
363. Blanchard-Fillion B, Souza JM, Friel T, et al. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 2001; 276(49): 46017-46023.
364. Sharma SK, Ebadi M. Metallothionein attenuates 3- morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid Redox Signal 2003; 5(3): 251-264.
365. Vauzour D, Ravaioli G, Vafeiadou K, Rodriguez-Mateos A, Angeloni C, Spencer JP. Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: implications for Parkinson's disease and protection by polyphenols. Arch Biochem Biophys 2008; 476(2): 145-151.
366. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997; 69(5): 1936-1944.
367. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264(5166): 1772-1775.
368. Baillet A, Chanteperdrix V, Trocme C, Casez P, Garrel C, Besson G. The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res; 35(10): 1530-1537.
369. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxidedependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999; 286(5449): 2498-2500.
370. Hooper DC, Bagasra O, Marini JC, et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 1997; 94(6): 2528-2533.
371. Hooper DC, Scott GS, Zborek A, et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. Faseb J 2000; 14(5): 691-698.
372. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95(2): 675-680.
373. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC. Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 2005; 102(9): 3483-3488.
374. Zingarelli B, Ischiropoulos H, Salzman AL, Szabo C. Amelioration by mercaptoethylguanidine of the vascular and energetic failure in haemorrhagic shock in the anesthetised rat. Eur J Pharmacol 1997; 338(1): 55-65.
375. Guven A, Uysal B, Akgul O, et al. Scavenging of peroxynitrite reduces renal ischemia/reperfusion injury. Ren Fail 2008; 30(7): 747-754.
376. Cabassi A, Dumont EC, Girouard H, et al. Effects of chronic Nacetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J Hypertens 2001; 19(7): 1233-1244.
377. Kizilgun M, Poyrazoglu Y, Oztas Y, et al. Beneficial effects of Nacetylcysteine and ebselen on renal ischemia/reperfusion injury. Ren Fail; 33(5): 512-517.
378. Tossios P, Bloch W, Huebner A, et al. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2003; 126(5): 1513-1520.
379. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med 2004; 21(2): 114-121.
380. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999; 26(11- 12): 1495-1500.
381. Sola S, Mir MQ, Cheema FA, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111(3): 343-348.
382. Ying Z, Kherada N, Farrar B, et al. Lipoic acid effects on established atherosclerosis. Life Sci; 86(3-4): 95-102.
383. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Jr., Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93(6): 1107-1113.
384. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97(22): 2222-2229.
385. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998; 31(3): 552-557.
386. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004): 781-786.
387. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356(9237): 1213-1218.
388. Xiong Y, Hall ED. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp Neurol 2009; 216(1): 105-114.
389. Deng-Bryant Y, Singh IN, Carrico KM, Hall ED. Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J Cereb Blood Flow Metab 2008; 28(6): 1114-1126.
390. Sepodes B, Maio R, Pinto R, et al. Tempol, an intracelullar free radical scavenger, reduces liver injury in hepatic ischemiareperfusion in the rat. Transplant Proc 2004; 36(4): 849-853.
391. Cuzzocrea S, McDonald MC, Mazzon E, et al. Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 2001; 29(1): 102-111.
392. Cuzzocrea S, McDonald MC, Mazzon E, et al. Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion. Shock 2000; 14(2): 150-156.
393. Cuzzocrea S, McDonald MC, Filipe HM, et al. Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan- induced pleurisy. Eur J Pharmacol 2000; 390(1-2): 209-222.
394. Kostyuk VA, Kraemer T, Sies H, Schewe T. Myeloperoxidase/ nitrite-mediated lipid peroxidation of low-density lipoprotein as modulated by flavonoids. FEBS Lett 2003; 537(1-3): 146-150.
395. Steffen Y, Schewe T, Sies H. Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase. Biochem Biophys Res Commun 2005; 331(4): 1277-1283.
396. Heiss C, Dejam A, Kleinbongard P, Schewe T, Sies H, Kelm M. Vascular effects of cocoa rich in flavan-3-ols. Jama 2003; 290(8): 1030-1031.
397. Heiss C, Kleinbongard P, Dejam A, et al. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 2005; 46(7): 1276-1283.
398. Belguendouz L, Fremont L, Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 1997; 53(9): 1347-1355.
399. Poussier B, Cordova AC, Becquemin JP, Sumpio BE. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 2005; 42(6): 1190-1197.
400. Wang Z, Huang Y, Zou J, Cao K, Xu Y, Wu JM. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002; 9(1): 77-79.
401. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005; 16(4): 533-540.
402. Muijsers RB, van Den Worm E, Folkerts G, et al. Apocynin inhibits peroxynitrite formation by murine macrophages. Br J Pharmacol 2000; 130(4): 932-936.
403. Vlahos R, Stambas J, Bozinovski S, Broughton BR, Drummond GR, Selemidis S. Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation. PLoS Pathog; 7(2): e1001271.
404. Stielow C, Catar RA, Muller G, et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006; 344(1): 200-205.
405. ten Freyhaus H, Huntgeburth M, Wingler K, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006; 71(2): 331-341.
406. Wind S, Beuerlein K, Armitage ME, et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension; 56(3): 490-497.
407. Cayatte AJ, Rupin A, Oliver-Krasinski J, et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 2001; 21(10): 1577-1584.
408. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001; 89(5): 408-414.
409. He Y, Cui J, Lee JC, et al. Prolonged exposure of cortical neurons to oligomeric amyloid-beta impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (-)-epigallocatechin-3-gallate. ASN Neuro; 3(1).
410. Ikeda Y, Young LH, Scalia R, Ross CR, Lefer AM. PR-39, a proline/arginine-rich antimicrobial peptide, exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc Res 2001; 49(1): 69-77.
411. Farley KS, Wang L, Mehta S. Septic pulmonary microvascular endothelial cell injury: role of alveolar macrophage NADPH oxidase. Am J Physiol Lung Cell Mol Physiol 2009; 296(3): L480-L488.
412. Kitada M, Koya D, Sugimoto T, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52(10): 2603-2614.
413. Nagareddy PR, Soliman H, Lin G, et al. Selective inhibition of protein kinase C beta(2) attenuates inducible nitric oxide synthasemediated cardiovascular abnormalities in streptozotocin-induced diabetic rats. Diabetes 2009; 58(10): 2355-2364.
414. Egi K, Conrad NE, Bedynek A, Ferdinandy P, Reichart B, Wildhirt SM. Improvement of cardiac allograft function by 1400W, a highly selective inducible nitric oxide synthase inhibitor and superoxide dismutase - role of peroxynitrite. J Heart Lung Transplant 2001; 20(2): 154.
415. Ersoz N, Guven A, Cayci T, et al. Comparison of the efficacy of melatonin and 1400W on renal ischemia/reperfusion injury: a role for inhibiting iNOS. Ren Fail 2009; 31(8): 704-710.
416. Gong L, Liu FQ, Wang J, et al. Hyperglycemia induces apoptosis of pancreatic islet endothelial cells via reactive nitrogen speciesmediated Jun N-terminal kinase activation. Biochim Biophys Acta Jun; 1813(6): 1211-1219.
417. Alderton WK, Angell AD, Craig C, et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 2005; 145(3): 301-312.
418. Dugo L, Marzocco S, Mazzon E, et al. Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 2004; 141(6): 979-987.
419. Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med; 50(5): 633-640.
420. Tiso M, Strub A, Hesslinger C, Kenney CT, Boer R, Stuehr DJ. BYK 191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3h-imidazo [4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase. Mol Pharmacol 2008; 73(4): 1244-1253.
421. Strub A, Ulrich WR, Hesslinger C, et al. The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK 191023) is a highly selective inhibitor of the inducible nitricoxide synthase. Mol Pharmacol 2006; 69(1): 328-337.
422. Su F, Huang H, Akieda K, et al. Effects of a selective iNOS inhibitor versus norepinephrine in the treatment of septic shock. Shock; 34(3): 243-249.
423. Lehner MD, Marx D, Boer R, et al. In vivo characterization of the novel imidazopyridine BYK 191023 [2-[2-(4-methoxy-pyridin-2- yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase. J Pharmacol Exp Ther 2006; 317(1): 181-187.
424. O'Neill MJ, Murray TK, McCarty DR, et al. ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res 2000; 871(2): 234-244.
425. Zhang ZG, Reif D, Macdonald J, et al. ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1996; 16(4): 599-604.
426. Babu BR, Griffith OW. N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase. J Biol Chem 1998; 273(15): 8882-8889.
427. Blasko E, Glaser CB, Devlin JJ, et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem 2002; 277(1): 295-302.
428. Davey DD, Adler M, Arnaiz D, et al. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors. J Med Chem 2007; 50(6): 1146-1157.
429. Enkhbaatar P, Wang J, Saunders F, et al. Mechanistic aspects of inducible nitric oxide synthase-induced lung injury in burn trauma. Burns; 37(4): 638-645.
430. Ichinose F, Hataishi R, Wu JC, et al. A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice. Am J Physiol Heart Circ Physiol 2003; 285(6): H2524-H2530.
431. Lange M, Connelly R, Traber DL, et al. Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury. Crit Care Med 2009; 37(1): 223-229.
432. Szabolcs MJ, Sun J, Ma N, et al. Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation 2002; 106(18): 2392-2396.
433. Symons KT, Massari ME, Nguyen PM, et al. KLYP956 is a nonimidazole- based orally active inhibitor of nitric-oxide synthase dimerization. Mol Pharmacol 2009; 76(1): 153-162.
434. Symons KT, Nguyen PM, Massari ME, et al. Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. J Pharmacol Exp Ther; 336(2): 468-478.
435. Cuzzocrea S, Misko TP, Costantino G, et al. Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. Faseb J 2000; 14(9): 1061-1072.
436. Nin N, Cassina A, Boggia J, et al. Septic diaphragmatic dysfunction is prevented by Mn(III)porphyrin therapy and inducible nitric oxide synthase inhibition. Intensive Care Med 2004; 30(12): 2271-2278.
437. Nin N, El-Assar M, Sanchez C, et al. Vascular Dysfunction in Sepsis: Effects of the Peroxynitrite Decomposition Catalyst MnTMPyP. Shock Mar 8.
438. Sompol P, Ittarat W, Tangpong J, et al. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stressmediated mitochondrial injury. Neuroscience 2008; 153(1): 120-130.
439. Rabbani ZN, Spasojevic I, Zhang X, et al. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2- yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med 2009; 47(7): 992-1004.
440. Cernanec JM, Weinberg JB, Batinic-Haberle I, Guilak F, Fermor B. Influence of oxygen tension on interleukin 1-induced peroxynitrite formation and matrix turnover in articular cartilage. J Rheumatol 2007; 34(2): 401-407.
441. Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998; 29(1): 12-17.
442. Okun E, Arumugam TV, Tang SC, et al. The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J Neurochem 2007; 102(4): 1232-1241.
443. Cassina P, Cassina A, Pehar M, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci 2008 16; 28(16): 4115-4122.
444. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. Faseb J 2005; 19(9): 1088-1095.